Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

Year: 2022

NSV News Portfolio News
Paragraf raises $60 million in Series B financing
March 1, 2022

Paragraf raises $60 million in Series B financing

Paragraf has announced the close of its $60m Series B round. The round is being led by New Science Ventures, a US deep tech investor, investing in novel scientific approaches in the Life Sciences and Information Technology sectors, which is very well aligned with Paragraf’s growth aspirations.  The round included

Read More
NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease
February 2, 2022

NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease

NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD. IFALD is a multifactorial condition

Read More
Cookie Policy Website powered by 100% renewable energy Privacy Policy